ArticleFrontiers in immunology2022

Immunosuppressant Treatment in Rheumatic Musculoskeletal Diseases Does Not Inhibit Elicitation of Humoral Response to SARS-CoV-2 Infection and Preserves Effector Immune Cell Populations.

Andrea Favalli et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.